These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36380413)

  • 1. Promises of Molecular Pharmaceutics in the Development of Novel Drug Delivery Formulations.
    Kumar P; Chaudhary B; Jain V; Baboota S; Shivanandy P; Alharbi KS; Ghoneim MM; Alshehri S; Imam SS; Gupta G; Gupta MM
    Curr Drug Deliv; 2023; 20(9):1262-1274. PubMed ID: 36380413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of drug product development.
    Narayan P
    Curr Protoc Pharmacol; 2011 Dec; Chapter 7():Unit 7.3.1-29. PubMed ID: 22147349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs.
    Pinheiro VA; Danopoulos P; Demirdjian L; Nogueira RJ; Dubois F
    Int J Pharm Compd; 2013; 17(5):424-31. PubMed ID: 24459788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining crystalline and polymeric excipients in API solid dispersions - Opportunity or risk?
    Veith H; Wiechert F; Luebbert C; Sadowski G
    Eur J Pharm Biopharm; 2021 Jan; 158():323-335. PubMed ID: 33296719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
    Buckley ST; Frank KJ; Fricker G; Brandl M
    Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective detection of active pharmaceutical ingredients in tablet formulations using solid-state NMR spectroscopy.
    Hong YL; Manjunatha Reddy GN; Nishiyama Y
    Solid State Nucl Magn Reson; 2020 Apr; 106():101651. PubMed ID: 32058901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voices in
    Moseson DE
    Mol Pharm; 2023 Aug; 20(8):3696-3697. PubMed ID: 37506188
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of the crystalline and amorphous states of drug products by nanothermal analysis and Raman imaging.
    Nakamoto K; Urasaki T; Hondo S; Murahashi N; Yonemochi E; Terada K
    J Pharm Biomed Anal; 2013 Mar; 75():105-11. PubMed ID: 23246930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solubility of pharmaceutical ingredients in triglycerides.
    Brinkmann J; Huxoll F; Luebbert C; Sadowski G
    Eur J Pharm Biopharm; 2019 Dec; 145():113-120. PubMed ID: 31682903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma sterilization of pharmaceuticals--a review of the irradiation of excipients, active pharmaceutical ingredients, and final drug product formulations.
    Hasanain F; Guenther K; Mullett WM; Craven E
    PDA J Pharm Sci Technol; 2014; 68(2):113-37. PubMed ID: 24668600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Support Tools in Formulation Development for Poorly Soluble Drugs.
    Fridgeirsdottir GA; Harris R; Fischer PM; Roberts CJ
    J Pharm Sci; 2016 Aug; 105(8):2260-9. PubMed ID: 27368122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Structure Pharmaceutics from Discovery to Evaluation and Design.
    Xu H; Wu L; Xue Y; Yang T; Xiong T; Wang C; He S; Sun H; Cao Z; Liu J; Wang S; Li Z; Naeem A; Yin X; Zhang J
    Mol Pharm; 2023 Sep; 20(9):4404-4429. PubMed ID: 37552597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive review on pharmaceutical excipients.
    Pockle RD; Masareddy RS; Patil AS; Patil PD
    Ther Deliv; 2023 Jul; 14(7):443-458. PubMed ID: 37464784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FIP Guidelines for Dissolution Testing of Solid Oral Products.
    Friedel HD; Brown CK; Barker AR; Buhse LF; Keitel S; Kraemer J; Morris JM; Reppas C; Sperry DC; Sakai-Kato K; Stickelmeyer MP; Shah VP
    J Pharm Sci; 2018 Dec; 107(12):2995-3002. PubMed ID: 30148985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Solid State NMR Investigation for Molecular States of Specialized Formulation to Improve the Water Solubility of Poorly Water-soluble Drugs].
    Higashi K
    Yakugaku Zasshi; 2021; 141(9):1063-1069. PubMed ID: 34471007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microfluidic Particle Engineering of Hydrophobic Drug with Eudragit E100─Bridging the Amorphous and Crystalline Gap.
    Shikha S; Lee YW; Doyle PS; Khan SA
    Mol Pharm; 2022 Nov; 19(11):4345-4356. PubMed ID: 36268657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.
    Lakshman JP; Cao Y; Kowalski J; Serajuddin AT
    Mol Pharm; 2008; 5(6):994-1002. PubMed ID: 19434852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selecting Excipients Forming Therapeutic Deep Eutectic Systems-A Mechanistic Approach.
    Wolbert F; Brandenbusch C; Sadowski G
    Mol Pharm; 2019 Jul; 16(7):3091-3099. PubMed ID: 31095911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitigating unwanted amorphisation: A screening method for the selection of suitable excipients.
    Amharar Y; Curtin V; Gallagher KH; O'Siochru E; O'Connell P; Healy AM
    Eur J Pharm Sci; 2016 Jan; 81():181-8. PubMed ID: 26493586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.